Merck: A High-Conviction Investment For Long-Term Growth [Seeking Alpha]
Harpoon Therapeutics, Inc. (HARP)
Last harpoon therapeutics, inc. earnings: 3/12 04:05 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
With a balanced portfolio and strategic acquisitions that include the Harpoon Therapeutics deal, Merck appears well-positioned to navigate challenges and reward investors along the way. Pros & Cons Pros: Resilience : Despite looming patent risks, Merck has shown resilience, with strong revenue growth driven by key products like KEYTRUDA. Dividend Commitment : Merck's recent dividend increase reflects its confidence in future growth. Innovative Pipeline : With a focus on innovation and strategic acquisitions like Harpoon Therapeutics, Merck shows potential for future growth and adaptation. Cons: Patent Risks : The impending patent cliff poses a significant risk to KEYTRUDA sales and overall revenue. Competitive Landscape : Merck operates in a highly competitive industry, facing challenges from rival companies and biosimilar competition, which could impact its market share and profitability - on a long-term basis. Test Drive iREIT© on Alpha For FREE (for 2 Weeks) Jo
Show less
Read more
Impact Snapshot
Event Time:
HARP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HARP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HARP alerts
High impacting Harpoon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HARP
News
- Harpoon Therapeutics, Inc. (NASDAQ: HARP) had its "neutral" rating re-affirmed by analysts at Citigroup Inc.. They now have a $23.00 price target on the stock, up previously from $13.00.MarketBeat
- INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, TARO, FFNWGlobeNewswire
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – HARP, FGH, BBAIAccesswire
- INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, JNPR, TGAN, TASTPR Newswire
- INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BBAI, HARP, FGH, PGTIPR Newswire
HARP
Sec Filings
- 3/12/24 - Form EFFECT
- 3/12/24 - Form EFFECT
- 3/12/24 - Form EFFECT
- HARP's page on the SEC website